Search - tctmd.com

Displaying 161 - 180 of 311

Sort: Relevancy | Date

Norepinephrine Bests Epinephrine in Battle of the Vasopressors in Cardiogenic Shock

News Daily News

Norepinephrine Bests Epinephrine in Battle of the Vasopressors in Cardiogenic Shock

July 03, 2018

Coronary CTA May Provide Novel Means of Predicting ACS Risk: ICONIC Study

News Daily News

Coronary CTA May Provide Novel Means of Predicting ACS Risk: ICONIC Study

June 01, 2018

STEMI Patients With Persistent Ischemia After PCI: A Potential Target for IABP?

News Conference News EuroPCR 2018

STEMI Patients With Persistent Ischemia After PCI: A Potential Target for IABP?

May 31, 2018

Chinese Firehawk Stent Performs Well Against Xience in All-Comers Study

News Conference News EuroPCR 2018

Chinese Firehawk Stent Performs Well Against Xience in All-Comers Study

Michael O'Riordan

May 29, 2018

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

News Daily News

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

April 18, 2018

TCTMD’s Top 10 Most Popular Stories for March 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2018

April 02, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

March 12, 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

March 05, 2018

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

iFR May Help Rule Out Significant Nonculprit Lesions After Primary PCI

News Daily News

iFR May Help Rule Out Significant Nonculprit Lesions After Primary PCI

November 30, 2017

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

Low High-Sensitivity Troponin I Cutoff May Allow Discharge From ED for Many

News Conference News AHA 2017

Low High-Sensitivity Troponin I Cutoff May Allow Discharge From ED for Many

November 11, 2017

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

News Conference News TCT 2017

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Michael O'Riordan

November 01, 2017

Long-term Absorb BVS Data Continue to Disappoint

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

CULPRIT-SHOCK Disputes Benefit of Immediate Multivessel PCI in Patients With Cardiogenic Shock

News Conference News TCT 2017

CULPRIT-SHOCK Disputes Benefit of Immediate Multivessel PCI in Patients With Cardiogenic Shock

October 30, 2017

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

News Daily News

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Yael L. Maxwell

October 03, 2017

Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds

News Daily News

Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds

Yael L. Maxwell

September 12, 2017

Supplemental Oxygen Provides No Benefit to Patients With Suspected MI: DETO2X-AMI

News Conference News ESC 2017

Supplemental Oxygen Provides No Benefit to Patients With Suspected MI: DETO2X-AMI

Michael O'Riordan

August 28, 2017

ESC Updates Guidelines for Treating STEMI Patients

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.